Cytomegalovirus infection pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Bot: Removing from Primary care)
 
(31 intermediate revisions by 3 users not shown)
Line 3: Line 3:
{{CMG}}; {{AE}}{{QS}}
{{CMG}}; {{AE}}{{QS}}
==Overview==
==Overview==
Transmission of [[CMV]] occurs from person to person and primary [[CMV infection]] causes activation of the [[immune system]] and resulting in a [[mononucleosis]] like presentation with [[hepatitis]] in [[immunocompromised]] individuals and few [[immunocompetent]] individuals. Reactivation can occur in response to [[inflammatory]] stimuli, physiologic [[stress]] and [[immunosuppression]] releasing new [[virions]] that can infect new cells causing [[CMV]] end organ infection.
==Pathophysiology==
==Pathophysiology==
===Genetics===
===Transmission===
As a result of efforts to create an [[attenuated virus]] [[vaccine]], there currently exist two general classes of CMV.  
*Transmission of [[CMV]] occurs from person to person.<ref name="pmid25205255">{{cite journal| author=Griffiths P, Baraniak I, Reeves M| title=The pathogenesis of human cytomegalovirus. | journal=J Pathol | year= 2015 | volume= 235 | issue= 2 | pages= 288-97 | pmid=25205255 | doi=10.1002/path.4437 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25205255  }} </ref>
*Infection requires close, intimate contact with a person excreting the virus in their [[saliva]], [[urine]], [[blood]], [[tears]], and [[semen]].
*The shedding of [[virus]] may take place intermittently, without any detectable signs, and without causing symptoms.
*CMV can be [[Sexually transmitted disease|sexually transmitted]] and can also be transmitted via [[Breastfeeding|breast milk]], transplanted organs, and rarely from [[blood transfusion]]s.<ref name=Sherris>{{cite book | author = Ryan KJ, Ray CG (editors) | title = Sherris Medical Microbiology | edition = 4th ed. | pages = pp. 556; 566–9 | publisher = McGraw Hill | year = 2004 | isbn = 0838585299 }}</ref>


* ''Clinical [[isolates]]'' comprise those viruses obtained from patients and represent the [[wild type]] viral [[genome]].
===Pathogenesis===
* ''Laboratory [[strain]]s'' have been [[culture]]d extensively in the lab setting and typically contain numerous accumulated [[mutation]]s. Most notably, the laboratory strain AD169 appears to lack a 15kb region of the 200kb genome that is present in clinical isolates. This region contains 19 [[open reading frame]]s whose functions have yet to be elucidated. AD169 is also unique in that it is unable to enter [[viral latency|latency]] and nearly always assumes [[lytic]] growth upon infection.
*Primary [[CMV infection]] causes activation of the [[immune system]] and results in a [[mononucleosis]] like presentation and its complications in [[immunocompromised]] individuals and few [[immunocompetent]] individuals.<ref>{{cite journal | author=Staras SAS, Dollard SC, Radford KW, ''et al.'' | title=Seroprevalence of cytomegalovirus infection in the United States, 1988&ndash;1994 | year=2006 | journal=Clin Infect Dis | volume=43 | pages=1143&ndash;51 | pmid = 17029132}}</ref><ref name="pmid25097085">{{cite journal| author=Goodman AL, Murray CD, Watkins J, Griffiths PD, Webster DP| title=CMV in the gut: a critical review of CMV detection in the immunocompetent host with colitis. | journal=Eur J Clin Microbiol Infect Dis | year= 2015 | volume= 34 | issue= 1 | pages= 13-8 | pmid=25097085 | doi=10.1007/s10096-014-2212-x | pmc=4281362 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25097085  }} </ref><ref name="pmid18371229">{{cite journal| author=Rafailidis PI, Mourtzoukou EG, Varbobitis IC, Falagas ME| title=Severe cytomegalovirus infection in apparently immunocompetent patients: a systematic review. | journal=Virol J | year= 2008 | volume= 5 | issue=  | pages= 47 | pmid=18371229 | doi=10.1186/1743-422X-5-47 | pmc=2289809 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18371229  }} </ref><ref name="pmid27460032">{{cite journal| author=Khan TV, Toms C| title=Cytomegalovirus Colitis and Subsequent New Diagnosis of Inflammatory Bowel Disease in an Immunocompetent Host: A Case Study and Literature Review. | journal=Am J Case Rep | year= 2016 | volume= 17 | issue=  | pages= 538-43 | pmid=27460032 | doi= | pmc=4968430 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27460032  }} </ref><ref name="pmid18194509">{{cite journal| author=Einbinder Y, Wolf DG, Pappo O, Migdal A, Tsvang E, Ackerman Z| title=The clinical spectrum of cytomegalovirus colitis in adults. | journal=Aliment Pharmacol Ther | year= 2008 | volume= 27 | issue= 7 | pages= 578-87 | pmid=18194509 | doi=10.1111/j.1365-2036.2008.03595.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18194509  }} </ref>
====Species====
*In majority of [[immunocompetent]] people, primary [[Cytomegalovirus infection|CMV infection]] is sub clinical and asymptomatic.
[[Image:CMVschema.svg|thumb|200px|left|Schema of CMV]]
*Following primary infection the [[virus]] persists in a latent form in the host tissues invading the [[immune system]].<ref name="pmid25772624">{{cite journal| author=Poole E, Sinclair J| title=Sleepless latency of human cytomegalovirus. | journal=Med Microbiol Immunol | year= 2015 | volume= 204 | issue= 3 | pages= 421-9 | pmid=25772624 | doi=10.1007/s00430-015-0401-6 | pmc=4439429 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25772624  }} </ref>
<br clear ="left"/>
*Reactivation can occur in response to [[inflammatory]] stimuli, physiologic [[stress]] and [[immunosuppression]] releasing new [[virions]] that can infect new cells causing cmv end organ infection.
*[[T-cells]] play a role in controlling the [[replication]] of the [[virus]].
*In patients with [[T cell|T-cell]] deficiency the viral [[replication]] is uncontrolled and results in excessive shedding of the [[virus]].
*Reactivation of the [[virus]] results in the release of [[cytokines]] such as  [[TNF-α]] and [[Interferon gamma|IFN-γ]] resulting in [[inflammation]].


{| class = "prettytable" style = "float:left; margin-left:15px"
===Genetics===
|-
*Patients with [[polymorphisms]] in the [[genes]] coding for mannose binding [[lectin]] and ficolin-2 are at a higher risk of developing [[CMV infection]].<ref name="pmid27108521">{{cite journal| author=Klenerman P, Oxenius A| title=T cell responses to cytomegalovirus. | journal=Nat Rev Immunol | year= 2016 | volume= 16 | issue= 6 | pages= 367-77 | pmid=27108521 | doi=10.1038/nri.2016.38 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27108521  }} </ref>
! Name !! Abv. !! Host
|-
| ''Cercopithecine herpesvirus 5'' || (CeHV-5) || African green monkey
|-
| ''Cercopithecine herpesvirus 8'' || (CeHV-8) || Rhesus monkey
|-
| ''[[Human herpesvirus 5]]'' || (HHV-5) || Humans
|-
| ''Pongine herpesvirus 4'' || (PoHV-4) || ?
|-
| ''Aotine herpesvirus 1'' || (AoHV-1) || (Tentative species)
|-
| ''Aotine herpesvirus 3'' || (AoHV-3) || (Tentative species)
|-
|}
<br clear ="left"/>


===Associated Conditions===
===Associated Conditions===
Specific disease entities recognised in [[immunocompromised]] people with CMV infection are [[cytomegalovirus retinitis]] (inflammation of the [[retina]], characterised by a "pizza pie appearance" on [[ophthalmoscopy]]) and cytomegalovirus [[colitis]] (inflammation of the [[colon (anatomy)|large bowel]]).
*Symptomatic [[cytomegalovirus]] is associated with [[HIV AIDS|HIV infection]] in majority of patients.<ref name="pmid27714898">{{cite journal| author=Grønborg HL, Jespersen S, Hønge BL, Jensen-Fangel S, Wejse C| title=Review of cytomegalovirus coinfection in HIV-infected individuals in Africa. | journal=Rev Med Virol | year= 2017 | volume= 27 | issue= 1 | pages=  | pmid=27714898 | doi=10.1002/rmv.1907 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27714898  }} </ref><ref name="pmid27625433">{{cite journal| author=Gianella S, Letendre S| title=Cytomegalovirus and HIV: A Dangerous Pas de Deux. | journal=J Infect Dis | year= 2016 | volume= 214 Suppl 2 | issue=  | pages= S67-74 | pmid=27625433 | doi=10.1093/infdis/jiw217 | pmc=5021239 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27625433  }} </ref>


===Microscopic Pathology===
===Microscopic Pathology===
Microscopically, CMV can be demonstrated by [[intranuclear]] [[inclusion]] bodies, which show that the [[virus]] replicates in the nucleus rather than the cytosol. These inclusion bodies stain dark pink on an [[H&E stain]], and are also called "Owl's Eye" inclusion bodies.
*[[CMV infection]] demonstrates the presence of [[intranuclear]] [[inclusion]] bodies. These [[inclusion bodies]] stain dark pink on an [[H&E stain]], and are also called "Owl's Eye" [[inclusion bodies]].
 
[[Lytic cycle|Lytically replicating]] virus disrupts the [[cytoskeleton]], causing massive cell enlargement, which is the source of the virus' name.
===Transmission===
Transmission of CMV occurs from person to person. [[Seroprevalence]] is age-dependent: 58.9% of individuals aged 6 and over are infected with CMV while 90.8% of individuals aged 80 and over are positive for CMV.<ref>{{cite journal | author=Staras SAS, Dollard SC, Radford KW, ''et al.'' | title=Seroprevalence of cytomegalovirus infection in the United States, 1988&ndash;1994 | year=2006 | journal=Clin Infect Dis | volume=43 | pages=1143&ndash;51 | pmid = 17029132}}</ref> Infection requires close, intimate contact with a person excreting the virus in their [[saliva]], [[urine]], [[blood]], [[tears]], and [[semen]]. The shedding of virus may take place intermittently, without any detectable signs, and without causing symptoms. CMV can be [[Sexually transmitted disease|sexually transmitted]] and can also be transmitted via [[Breastfeeding|breast milk]], transplanted organs, and rarely from [[blood transfusion]]s.
 
CMV is part of the association known as [[TORCH infections]] that lead to [[congenital abnormality|congenital abnormalities]].  These include [[Toxoplasmosis]], [[Rubella]], [[Herpes simplex]], as well as CMV, among others. The virus can also be transmitted to the infant at [[delivery]] from contact with [[genital]] [[secretion]]s or later in infancy through breast milk. However, these infections usually result in little or no clinical illness in the infant.
 
Although CMV is not highly contagious, it has been shown to spread in households and among young children in day care centers.<ref name=Sherris>{{cite book | author = Ryan KJ, Ray CG (editors) | title = Sherris Medical Microbiology | edition = 4th ed. | pages = pp. 556; 566–9 | publisher = McGraw Hill | year = 2004 | isbn = 0838585299 }}</ref>
 
Following transmission, the primary infection is usually asymptomatic in immunocompetent individuals. Latency state develops after the primary infection in immunocompetent individuals with CMV infection persisting in the host tissues by evading the immune system. Reactivation of the infection occurs in persons with latent CMV when the host's immune system becomes compromised. CMV usually colonizes inflamed tissues than healthy tissues. Cytokines such as TNF-α and IFN-γ, are released following local inflammation in the bowel wall. CMV gets to the mucosa of the colon through the macrophages. The cytokines reactivate latent CMV infection and promote the migration of CMV-infected macrophages to inflamed colon. This further causes damage to the tissue.<ref>{{cite journal | author=Staras SAS, Dollard SC, Radford KW, ''et al.'' | title=Seroprevalence of cytomegalovirus infection in the United States, 1988&ndash;1994 | year=2006 | journal=Clin Infect Dis | volume=43 | pages=1143&ndash;51 | pmid = 17029132}}</ref><ref name="pmid25097085">{{cite journal| author=Goodman AL, Murray CD, Watkins J, Griffiths PD, Webster DP| title=CMV in the gut: a critical review of CMV detection in the immunocompetent host with colitis. | journal=Eur J Clin Microbiol Infect Dis | year= 2015 | volume= 34 | issue= 1 | pages= 13-8 | pmid=25097085 | doi=10.1007/s10096-014-2212-x | pmc=4281362 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25097085  }} </ref><ref name="pmid18371229">{{cite journal| author=Rafailidis PI, Mourtzoukou EG, Varbobitis IC, Falagas ME| title=Severe cytomegalovirus infection in apparently immunocompetent patients: a systematic review. | journal=Virol J | year= 2008 | volume= 5 | issue=  | pages= 47 | pmid=18371229 | doi=10.1186/1743-422X-5-47 | pmc=2289809 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18371229  }} </ref><ref name="pmid27460032">{{cite journal| author=Khan TV, Toms C| title=Cytomegalovirus Colitis and Subsequent New Diagnosis of Inflammatory Bowel Disease in an Immunocompetent Host: A Case Study and Literature Review. | journal=Am J Case Rep | year= 2016 | volume= 17 | issue=  | pages= 538-43 | pmid=27460032 | doi= | pmc=4968430 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27460032  }} </ref><ref name="pmid18194509">{{cite journal| author=Einbinder Y, Wolf DG, Pappo O, Migdal A, Tsvang E, Ackerman Z| title=The clinical spectrum of cytomegalovirus colitis in adults. | journal=Aliment Pharmacol Ther | year= 2008 | volume= 27 | issue= 7 | pages= 578-87 | pmid=18194509 | doi=10.1111/j.1365-2036.2008.03595.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18194509  }} </ref>


==References==
==References==
Line 52: Line 34:
{{WH}}
{{WH}}
{{WS}}
{{WS}}
[[Category:Viral diseases]]
[[Category:Viral diseases]]
[[Category:Herpesviruses]]
[[Category:Herpesviruses]]
[[Category:Infectious disease]]
[[Category:Mature chapter]]
[[Category:Mature chapter]]
[[Category:Disease]]
[[Category:Disease]]
[[Category:Needs overview]]
[[Category:Needs overview]]
[[Category:Emergency medicine]]
[[Category:Up-To-Date]]
[[Category:Infectious disease]]
[[Category:Neurology]]
[[Category:Neurosurgery]]
[[Category:Gastroenterology]]
[[Category:Ophthalmology]]

Latest revision as of 21:13, 29 July 2020

Cytomegalovirus infection Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cytomegalovirus infection from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cytomegalovirus infection pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cytomegalovirus infection pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cytomegalovirus infection pathophysiology

CDC on Cytomegalovirus infection pathophysiology

Cytomegalovirus infection pathophysiology in the news

Blogs on Cytomegalovirus infection pathophysiology

Directions to Hospitals Treating Cytomegalovirus infection

Risk calculators and risk factors for Cytomegalovirus infection pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Qasim Salau, M.B.B.S., FMCPaed [2]

Overview

Transmission of CMV occurs from person to person and primary CMV infection causes activation of the immune system and resulting in a mononucleosis like presentation with hepatitis in immunocompromised individuals and few immunocompetent individuals. Reactivation can occur in response to inflammatory stimuli, physiologic stress and immunosuppression releasing new virions that can infect new cells causing CMV end organ infection.

Pathophysiology

Transmission

Pathogenesis

Genetics

Associated Conditions

Microscopic Pathology

References

  1. Griffiths P, Baraniak I, Reeves M (2015). "The pathogenesis of human cytomegalovirus". J Pathol. 235 (2): 288–97. doi:10.1002/path.4437. PMID 25205255.
  2. Ryan KJ, Ray CG (editors) (2004). Sherris Medical Microbiology (4th ed. ed.). McGraw Hill. pp. pp. 556, 566–9. ISBN 0838585299.
  3. Staras SAS, Dollard SC, Radford KW; et al. (2006). "Seroprevalence of cytomegalovirus infection in the United States, 1988–1994". Clin Infect Dis. 43: 1143&ndash, 51. PMID 17029132.
  4. Goodman AL, Murray CD, Watkins J, Griffiths PD, Webster DP (2015). "CMV in the gut: a critical review of CMV detection in the immunocompetent host with colitis". Eur J Clin Microbiol Infect Dis. 34 (1): 13–8. doi:10.1007/s10096-014-2212-x. PMC 4281362. PMID 25097085.
  5. Rafailidis PI, Mourtzoukou EG, Varbobitis IC, Falagas ME (2008). "Severe cytomegalovirus infection in apparently immunocompetent patients: a systematic review". Virol J. 5: 47. doi:10.1186/1743-422X-5-47. PMC 2289809. PMID 18371229.
  6. Khan TV, Toms C (2016). "Cytomegalovirus Colitis and Subsequent New Diagnosis of Inflammatory Bowel Disease in an Immunocompetent Host: A Case Study and Literature Review". Am J Case Rep. 17: 538–43. PMC 4968430. PMID 27460032.
  7. Einbinder Y, Wolf DG, Pappo O, Migdal A, Tsvang E, Ackerman Z (2008). "The clinical spectrum of cytomegalovirus colitis in adults". Aliment Pharmacol Ther. 27 (7): 578–87. doi:10.1111/j.1365-2036.2008.03595.x. PMID 18194509.
  8. Poole E, Sinclair J (2015). "Sleepless latency of human cytomegalovirus". Med Microbiol Immunol. 204 (3): 421–9. doi:10.1007/s00430-015-0401-6. PMC 4439429. PMID 25772624.
  9. Klenerman P, Oxenius A (2016). "T cell responses to cytomegalovirus". Nat Rev Immunol. 16 (6): 367–77. doi:10.1038/nri.2016.38. PMID 27108521.
  10. Grønborg HL, Jespersen S, Hønge BL, Jensen-Fangel S, Wejse C (2017). "Review of cytomegalovirus coinfection in HIV-infected individuals in Africa". Rev Med Virol. 27 (1). doi:10.1002/rmv.1907. PMID 27714898.
  11. Gianella S, Letendre S (2016). "Cytomegalovirus and HIV: A Dangerous Pas de Deux". J Infect Dis. 214 Suppl 2: S67–74. doi:10.1093/infdis/jiw217. PMC 5021239. PMID 27625433.

Template:WH Template:WS